The global hyperlipidemia drugs market size is projected expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the presence of novel drug classes with improved efficacy & safety and introduction of new guidelines that redefined at-risk patient groups.
Hyperlipidemia is a term for a variety of acquired or inherited diseases associated with high amount of lipids such as fats, cholesterol, and triglycerides in the bloodstream. Triglycerides and cholesterol are the two main types of lipids present in the blood. Triglycerides are formed when your body retains excess calories that it does not require for energy. Triglycerides are raised by a diet rich in refined sugar, fructose, and alcohol. Because every cell in your body requires cholesterol, it is generated naturally in your liver. Cholesterol, like triglycerides, is present in fatty meals like eggs, red meat, and cheese. High cholesterol is a term used to describe hyperlipidemia.
Although high cholesterol can be passed down the generations, it is more commonly the result of poor lifestyle choices. As hyperlipidemia has no symptoms, a blood test called a lipid panel, or a lipid profile is the only method to identify it. Cholesterol levels are determined by this test. The doctor will take a sample of blood and send it to a lab for testing. Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides are all included in the report. LDL and HDL are the two types of cholesterol. The terms bad and good cholesterol are commonly used to describe them. LDL (bad) cholesterol builds up in the walls of your arteries, hardening and narrowing them. HDL (good) cholesterol removes extra bad cholesterol from the arteries and transports it to the liver.
Hyperlipidemia is a condition in which your blood has too much LDL cholesterol and not enough HDL cholesterol to remove it. Eating foods high in saturated and trans fats, eating animal protein such as meat and dairy, not getting enough exercise, not eating enough healthy fats, obesity, a large waist circumference, smoking, and excessive alcohol consumption are all lifestyle choices that increases risk for high cholesterol. Some persons with specific health problems, such as renal illness, diabetes, polycystic ovarian syndrome, pregnancy, underactive thyroid, and hereditary disorders, have abnormal cholesterol levels.
The key to treating hyperlipidemia at home is to make lifestyle modifications. Even if you have hereditary hyperlipidemia (familial mixed hyperlipidemia), lifestyle modifications are still necessary for therapy. These modifications may be sufficient to lower your risk of problems such as heart disease and stroke. If a patient is currently taking medicines to reduce cholesterol, making lifestyle modifications might help them work even better. Diet and lifestyle modifications may be sufficient for some people to lower their cholesterol levels to a healthy level. Others may require additional assistance. Statins are drugs that stop your liver from producing cholesterol. They are a popular choice for lowering cholesterol levels in the blood. A novel type of medication prevents cholesterol from being absorbed into your body through your gut. They are known as cholesterol absorption inhibitors, and they operate in tandem with statins. The medication ezetimibe is an example (Zetia). Another form of medicine, resins, deceive the body into burning cholesterol. They attach to bile, a digestive acid, preventing it from doing its purpose. The liver must produce more bile, which necessitates the use of cholesterol. As a result, there is less cholesterol in the circulation. There might be additional new therapy alternatives to think about. It is advisable to speak with your doctor about this. Hyperlipidemia is generally a chronic condition that necessitates the use of statin medications to keep blood lipid levels under control.
Market Segment Insights
Based on drug class, the hyperlipidemia drugs market is segmented into statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination, and miscellaneous antihyperlipidemic agents. Miscellaneous antihyperlipidemic segment is further sub segmented into omega-3 fatty acids, nicotinic acids, lomitapide, mipomersen, and bempedoic acid. The PCSK9 inhibitors segment is expected to account for a key share of the market during the forecast period owing to its improved efficacy, lower cost, and safety profile. Introduction of more effective treatments such as PCSK9 inhibitors and bempedoic acid, the market for statins is expected to drop throughout the forecast period. For the treatment of homozygous FH patients, PCSK9 inhibitors are likely to substitute existing costly treatments such as lomitapide and mipomersen.
On the other hand, the Miscellaneous antihyperlipidemic segment is anticipated to expand at a rapid pace during the forecast period owing to its improved safety and performance characteristics of pipeline drugs and increased acceptance among end users. Furthermore, this drug class's improved efficacy compared to statins, as well as its efficacy to lower the risk of CVD in ongoing clinical trials, are expected to drive the segment growth.
On the basis of regions, the hyperlipidemia drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America and Europe is anticipated to dominate the market CAGR during the forecast period. The regional market growth can be attributed to increasing prevalence of hypercholesterolemia, with higher levels of lipoproteins and the rising baby boomer generation.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to highly established health care infrastructure and a higher acceptance rate of technologically sophisticated treatment goods. Furthermore, the aging population and increased awareness of heart disease are two factors driving the hyperlipidemia drug market. However, due to the non-availability of major revenue-generating medicines like bempedoic acid, Japan's hyperlipidemia market has fewer growth potential.
Get Sample Report @ Request For Sample of Hyperlipidemia Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast | Growth Market Reports
Key Players Covered in the Report
Amgen Inc.; AstraZeneca PLC; Daiichi Sankyo Company Limited; Eli Lilly and Company; Esperion Therapeutics Inc.; GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc); Immuron Limited; Ionis Pharmaceuticals Inc.; Merck & Co. Inc.; Pfizer Inc.; and Sanofi S.A.
About Growth Market Reports:
Growth Market Reports provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. Growth Market Reports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
According to the latest report by IMARC Group “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026“, The global hyperlipidemia drugs market is expected to exhibit stable growth during 2021-2026.Hyperlipidemia refers to a condition that causes abnormally high levels of fats or lipids in the blood.
The disorder may lead to cardiac stroke, peripheral vascular diseases, obesity, hypertension, and cardiovascular disorders(CVDs).
Statins are the primary line of treatment in secondary hyperlipidemia caused by an unhealthy lifestyle.
Some of the other common drugs used in the treatment of hyperlipidemia are bile acid sequestrants, PCSK9, and miscellaneous antihyperlipidemic agents, which help reduce the production of cholesterol in the liver.
They also lower the number of lipids in the bloodstream and reduce inflammation and damage done to the cells.Request for a free sample copy of this report: https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsampleNote: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries.
In addition to this, the upcoming patent expiration has resulted in the genericization of statin and cholesterol absorption inhibitors, which is significantly augmenting the market growth.
Pharmaceutical Glass Packaging Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Pharmaceutical Glass Packaging Market Research Report, Product, Application and Region - Forecast till 2027”, The global Pharmaceutical Glass Packaging Market is projected to reach USD 13.5 billion by 2027 from an estimated USD 7.6 billion in 2020, at a CAGR of 6.9% from 2021 to 2027.The pharmaceutical glass packaging market outlook appears extremely positive.
Moreover, the rising preference for environment-friendly packaging solutions impacts pharmaceutical glass packaging adoption.Demand for eco-friendly pharmaceutical glass packaging solutions, such as malleability and non-reactive nature, allows the market to witness an upward trajectory.
Browse In-depth Market Research Report (111 pages) on Pharmaceutical Glass Packaging https://www.marketresearchfuture.com/reports/pharmaceutical-glass-packaging-market-5179 For instance, recently, on June 14, 2021, SCHOTT, a leading pharmaceutical glass packaging solution provider, announced investments in smart skin technologies.
Smart Skin offers a monitoring system helping pharma companies to run pharmaceutical containers smoothly on the lines, saving time and money.SCHOTT’s pharmaceutical containers and high-quality glass vials are used in 75 % of all COVID-19 vaccine projects approved or are currently in the pipeline, including projects funded by the US Operation Warp Speed program.On Jan.13, 2021, SCHOTT had announced producing record-breaking pharmaceutical containers, including critical glass vials, as the US prepares for COVID-19 vaccine distribution.
With the healthcare industry’s focus on scaling up approved vaccine production, proven and safe pharmaceutical primary packaging has become crucial to accelerate rapid drug distribution while ensuring patient safety.
Initiatives from public and private sectors worldwide to prioritize the production, packaging, distribution, and administration of the vaccine are expected to foster the production of pharmaceutical glass vials.
The global creatinine measurement market size is expected to reach USD 841.01 million by 2028 at a CAGR of 8.3%, according to the latest report by Reports and Data.
The market revenue growth is attributed to rising prevalence of renal disorders, especially in developing countries, and rising awareness regarding preventive healthcare approaches globally.
Creatinine is basically a synthesized blood chemical waste product, which passes through kidneys to be filtered and gets eliminated through urine.
Key companies operating in the global market and profiled in the report include: Hoffmann-la Roche ltd. (Switzerland), Danaher Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific (U.S.), Randox Laboratories (UK), Siemens Healthineers (Germany), Pointe Scientific (U.S.), Diasys Diagnostic Systems GmbH (Germany), Diazyme Laboratories (U.S.), Sentinel Ch.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/4052Further key findings in the reportJaffe’s kinetic method segment is expected to register largest revenue share in the creatinine measurement market during the forecast period, due to its ability of creatinine measurement in a wide range of clinical samples.
Hospitals segment is predicted to occupy fastest revenue CAGR in the global market going ahead.
